Back to Search Start Over

Safety of vitamin D 2 mushroom powder as a Novel food pursuant to Regulation (EU) 2015/2283 (NF 2020/2226).

Authors :
Turck D
Bohn T
Castenmiller J
De Henauw S
Hirsch-Ernst KI
Maciuk A
Mangelsdorf I
McArdle HJ
Naska A
Pentieva K
Siani A
Thies F
Tsabouri S
Vinceti M
Aguilera-Gómez M
Cubadda F
Frenzel T
Heinonen M
Marchelli R
Neuhäuser-Berthold M
Poulsen M
Prieto Maradona M
Schlatter JR
Siskos A
van Loveren H
Gerazova-Efremova K
Roldán-Torres R
Knutsen HK
Source :
EFSA journal. European Food Safety Authority [EFSA J] 2024 Jun 12; Vol. 22 (6), pp. e8817. Date of Electronic Publication: 2024 Jun 12 (Print Publication: 2024).
Publication Year :
2024

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on vitamin D <subscript>2</subscript> mushroom powder as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced from Agaricus bisporus mushroom powder that has been exposed to ultraviolet (UV) irradiation to induce the conversion of provitamin D <subscript>2</subscript> (ergosterol) to vitamin D <subscript>2</subscript> (ergocalciferol). The NF contains concentrations of vitamin D in the form of vitamin D <subscript>2</subscript> in the range of 245-460 μg/g. The information provided on the production process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF as an ingredient in a variety of foods and beverages in amounts that result in either 1.2 or 2.4 μg vitamin D <subscript>2</subscript> per 100 g or 100 mL of the food as consumed. The applicant also intends to add the NF in food supplements at a maximum of 15 μg vitamin D <subscript>2</subscript> /day for individuals above 1 year of age, as well as in foods for special medical purposes (FSMPs). The estimates for combined intake of vitamin D from the NF, the background diet and fortified foods, were below the ULs for vitamin D as established previously by the NDA Panel for children, adolescents and adults, i.e. 50 and 100 μg/day. The estimated combined vitamin D intake in infants (6-12 months) is also below the UL for vitamin D of 35 μg/day. The Panel considers that taking into account the composition of the NF and the proposed conditions of use, the consumption of the NF is not nutritionally disadvantageous for the proposed target population. The Panel concludes that the NF is safe under the proposed conditions of use.<br />Competing Interests: If you wish to access the declaration of interests of any expert contributing to an EFSA scientific assessment, please contact interestmanagement@efsa.europa.eu.<br /> (© 2024 European Food Safety Authority. EFSA Journal published by Wiley‐VCH GmbH on behalf of European Food Safety Authority.)

Details

Language :
English
ISSN :
1831-4732
Volume :
22
Issue :
6
Database :
MEDLINE
Journal :
EFSA journal. European Food Safety Authority
Publication Type :
Academic Journal
Accession number :
38868108
Full Text :
https://doi.org/10.2903/j.efsa.2024.8817